Sagun Parakh

Loading... 2 0 20 0 false
Credit Name
Sagun Parakh
Full Name
Parakh, Sagun
 
Department
 
Loading... 3 0 20 0 false

Publications

Results 1-20 of 53 (Search time: 0.008 seconds).

Publication YearTitleAuthor(s)
130-Jan-2024Implementation of a nurse-led, multidisciplinary model of care for older adults with cancer: a process evaluation protocol.Dufton, Polly Hypatia; Tarasenko, Elena; Midgley, Katrina; Lee, Kathryn; Kelly, Ray; Rodrigues, Jeremy; Yates, Paul A ; Arulananda, Surein; Parakh, Sagun 
213-Nov-2023Antibody drug conjugates for glioblastoma: current progress toward clinical use.Gan, Hui K ; Parakh, Sagun ; Osellame, Laura D; Cher, Lawrence M ; Uccellini, Anthony; Hafeez, Umbreen ; Menon, Siddharth; Scott, Andrew M 
31-Nov-2023PD-L1 PET imaging in patients with NSCLC: Preliminary results of the ImmunoPET Phase 0 study.Hegi-Johnson, Fiona; Rudd, Stacey E; Wichmann, Christian W; Akhurst, Tim; Roselt, Peter; Sursock, Sandra; Trinh, Jenny; John, Thomas ; Devereux, Lisa; Donnelly, Paul S; Hicks, Rodney J; Scott, Andrew M ; Steinfort, Daniel; Fox, Stephen; Blyth, Benjamin; Parakh, Sagun ; Hanna, Gerard G; Callahan, Jason; Burbury, Kate; MacManus, Michael
4Aug-2023Real-World Analysis of Clinical Characteristics and Survival Outcomes in Patients With Extensive-Stage SCLC Treated With First-Line Chemoimmunotherapy.Wang, Yang; Mathai, Jared; Alamgeer, Muhammad; Parakh, Sagun ; Paul, Eldho; Mitchell, Paul L R ; Arulananda, Surein
531-Jul-2023Real-world challenges in undertaking NTRK fusion testing in non-small cell lung cancer.Poh, Ashleigh; Sammour, Abdelaziz; Mathai, Jared; Peverall, Joanne; Van Vliet, Chris; Asadi, Khashayar ; Parakh, Sagun 
6Apr-2023LOREALAUS: LOrlatinib REAL-World AUStralian Experience in Advanced ALK-Rearranged NSCLC.Alexander, Marliese; Wei, Joe; Parakh, Sagun ; John, Thomas ; Kao, Steven; Nagrial, Adnan; Bowyer, Samantha; Warburton, Lydia; Moore, Melissa; Hughes, Brett G M; Clay, Timothy D; Pavlakis, Nick; Solomon, Benjamin J; Itchins, Malinda
72023Editorial: Overcoming drug relapse and therapy resistance in NSCLC.Parakh, Sagun ; Leong, Tracy L ; Best, Sarah A; Poh, Ashleigh R
8Dec-2022A Multi-Center Real-World Experience of IMpower150 in Oncogene Driven Tumors and CNS Metastases.Itchins, Malinda; Ainsworth, Hannah; Alexander, Marliese; Dean, Samantha; Dharmaraj, Devi; Pavlakis, Nick; Clarke, Stephen J; Brown, Chris; Torres, Javier; Saqib, Ayesha; Ladwa, Rahul; O'Byrne, Kenneth; Moore, Melissa; Yip, Po Yee; Solomon, Ben; John, Tom ; Kao, Steven; Mitchell, Paul L R ; Parakh, Sagun 
918-Nov-2022ImmunoPET: IMaging of cancer imMUNOtherapy targets with positron Emission Tomography: a phase 0/1 study characterising PD-L1 with 89Zr-durvalumab (MEDI4736) PET/CT in stage III NSCLC patients receiving chemoradiation study protocol.Hegi-Johnson, Fiona; Rudd, Stacey E; Wichmann, Christian; Akhurst, Tim; Roselt, Peter; Trinh, Jenny; John, Thomas ; Devereux, Lisa; Donnelly, Paul S; Hicks, Rod; Scott, Andrew M ; Steinfort, Daniel; Fox, Stephen; Blyth, Benjamin; Parakh, Sagun ; Hanna, Gerard G; Callahan, Jason; Burbury, Kate; MacManus, Michael
1022-Aug-2022Correction to: Poor correlation between preclinical and patient efficacy data for tumor targeted monotherapies in glioblastoma: the results of a systematic review.Gunjur, Ashray ; Balasubramanian, Adithya ; Hafeez, Umbreen ; Menon, Siddharth; Cher, Lawrence M ; Parakh, Sagun ; Gan, Hui K 
116-Aug-2022Poor correlation between preclinical and patient efficacy data for tumor targeted monotherapies in glioblastoma: the results of a systematic review.Gunjur, Ashray ; Balasubramanian, Adithya ; Hafeez, Umbreen ; Menon, Siddharth; Cher, Lawrence M ; Parakh, Sagun ; Gan, Hui K 
12Aug-2022Adult medulloblastoma in an Australian population.Parakh, Sagun ; Davies, Amy; Westcott, Kerryn; Roos, Daniel; Abou-Hamden, Amal; Ahern, Elizabeth; Lau, Peter K H; Cheruvu, Sowmya; Pranavan, Ganesalingam; Pullar, Andrew; Lynam, James; Gzell, Cecelia; Whittle, James R; Cain, Sarah; Inglis, Po-Ling; Harrup, Rosemary; Anazodo, Antoinette; Hovey, Elizabeth; Cher, Lawrence M ; Gan, Hui K 
13Aug-2022A phase 1 safety and bioimaging trial of antibody DS-8895a against EphA2 in patients with advanced or metastatic EphA2 positive cancers.Gan, Hui K ; Parakh, Sagun ; Lee, Fook-Thean; Tebbutt, Niall C ; Ameratunga, Malaka; Lee, Sze Ting ; O'Keefe, Graeme J; Gong, Sylvia J; Vanrenen, Christine; Caine, Jaren; Giovannetti, Mara; Murone, Carmel ; Scott, Fiona E; Guo, Nancy; Burvenich, Ingrid J G; Paine, Cameron; Macri, Mary J; Kotsuma, Masakatsu; Senaldi, Giorgio; Venhaus, Ralph; Scott, Andrew M 
14May-2022Primary CNS lymphoma in the real world-Opportunities for improved outcomes in different health settingsParakh, Sagun ; Gan, Hui K 
1518-Apr-2022Lung cancer in non-smokers: a diagnosis of increasing importance.Dean, Samantha; Lennox, Rachel; Senko, Clare ; Parakh, Sagun 
1611-Mar-2022Radiolabeled Antibodies for Cancer Imaging and Therapy.Parakh, Sagun ; Lee, Sze Ting ; Gan, Hui K ; Scott, Andrew M 
173-Mar-2022The systemic management of central nervous system metastases and leptomeningeal disease from advanced lung, melanoma, and breast cancer with molecular drivers: An Australian perspective.Senko, Clare ; Gunjur, Ashray ; Balasubramanian, Adithya ; Gan, Hui K ; Parakh, Sagun ; Cher, Lawrence M 
182022Antibody-drug conjugates: beyond current approvals and potential future strategies.Menon, Siddharth; Parakh, Sagun ; Scott, Andrew M ; Gan, Hui K 
1911-Dec-2021Multicellular Effects of STAT3 in Non-small Cell Lung Cancer: Mechanistic Insights and Therapeutic Opportunities.Parakh, Sagun ; Ernst, Matthias ; Poh, Ashleigh R
203-Dec-2021Antibody Drug Conjugates in Glioblastoma - Is There a Future for Them?Parakh, Sagun ; Nicolazzo, Joseph; Scott, Andrew M ; Gan, Hui K